Inhibikase Therapeutics (IKT) Earnings Date, Estimates & Call Transcripts $2.36 -0.06 (-2.48%) (As of 11/14/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Inhibikase Therapeutics Latest Earnings SummaryLatest Q2 2024 Earnings DateAug. 14EstimatedActual EPS (Aug. 14) -$0.66 Missed By -$0.08 Consensus EPS (Aug. 14) -$0.58 Inhibikase Therapeutics released Q2 2024 earnings on August 14, 2024, reporting an EPS of -$0.66, which missed the consensus estimate of -$0.58 by $0.08. With a trailing EPS of -$2.88, Inhibikase Therapeutics' earnings are expected to grow next year, from ($0.68) to ($0.34) per share. Get Inhibikase Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIKT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IKT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Click here to reserve your seat at the Crypto Community Summit. Inhibikase Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.79-$0.79-$0.79Q2 20241-$0.58-$0.58-$0.58Q3 20241-$0.37-$0.37-$0.37Q4 20241-$0.37-$0.37-$0.37FY 20244($2.11)($2.11)($2.11) Inhibikase Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks8/14/2024Q2 2024-$0.58-$0.66 -$0.08-$0.66--5/15/2024Q1 2024-$0.79-$0.73+$0.06-$0.73--3/27/2024Q4 2023-$0.78-$0.63+$0.15-$0.63-- 11/14/2023Q3 2023-$1.12-$0.86+$0.26-$0.86-$0.08M8/14/2023Q2 2023-$0.92-$1.11 -$0.19-$1.11-$0.12M 5/15/2023Q1 2023-$0.90-$0.96 -$0.06-$0.16-$0.07M Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/31/2023Q4 2022--$1.02 -$1.02-$0.17-$0.06M11/14/2022Q3 2022--$1.08 -$1.08-$0.18-$0.01M Inhibikase Therapeutics Earnings - Frequently Asked Questions When did Inhibikase Therapeutics announce their last quarterly earnings? Inhibikase Therapeutics (NYSE:IKT) last announced its quarterly earning data on Wednesday, August 14, 2024. Learn more on IKT's earnings history. Did Inhibikase Therapeutics beat their earnings estimates last quarter? In the previous quarter, Inhibikase Therapeutics (NYSE:IKT) missed the analysts' consensus estimate of ($0.58) by $0.08 with a reported earnings per share (EPS) of ($0.66). Learn more on analysts' earnings estimate vs. IKT's actual earnings. How much revenue does Inhibikase Therapeutics generate each year? Inhibikase Therapeutics (NYSE:IKT) has a recorded annual revenue of $260,000.00. How much profit does Inhibikase Therapeutics generate each year? Inhibikase Therapeutics (NYSE:IKT) has a recorded net income of -$19.03 million. IKT has generated -$2.88 earnings per share over the last four quarters. What is Inhibikase Therapeutics's EPS forecast for next year? Inhibikase Therapeutics's earnings are expected to grow from ($0.68) per share to ($0.34) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies MGX Earnings Results DBVT Earnings Results ZIVO Earnings Results ENTX Earnings Results OMGA Earnings Results DTIL Earnings Results QNCX Earnings Results TARA Earnings Results CVM Earnings Results ATRA Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Click here to reserve your seat at the Crypto Community Summit. This page (NYSE:IKT) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
